Russell Investments Group Ltd. Purchases New Stake in Coherus BioSciences, Inc. (NASDAQ:CHRS)

Russell Investments Group Ltd. purchased a new stake in Coherus BioSciences, Inc. (NASDAQ:CHRS) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 73,102 shares of the biotechnology company’s stock, valued at approximately $243,000.

Several other hedge funds have also added to or reduced their stakes in CHRS. Dorsey & Whitney Trust CO LLC acquired a new position in Coherus BioSciences in the third quarter valued at about $39,000. China Universal Asset Management Co. Ltd. lifted its stake in Coherus BioSciences by 430.9% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 12,880 shares of the biotechnology company’s stock valued at $43,000 after buying an additional 10,454 shares during the period. Vontobel Holding Ltd. acquired a new position in Coherus BioSciences in the fourth quarter valued at about $50,000. ELCO Management Co. LLC acquired a new position in Coherus BioSciences in the third quarter valued at about $57,000. Finally, Sherbrooke Park Advisers LLC acquired a new position in Coherus BioSciences in the third quarter valued at about $66,000. Institutional investors own 72.82% of the company’s stock.

Coherus BioSciences Price Performance

Shares of NASDAQ CHRS opened at $2.11 on Thursday. The stock has a market capitalization of $242.07 million, a PE ratio of -2.71 and a beta of 0.56. The business has a fifty day moving average price of $2.22 and a two-hundred day moving average price of $2.32. Coherus BioSciences, Inc. has a fifty-two week low of $1.43 and a fifty-two week high of $5.63.

Coherus BioSciences (NASDAQ:CHRS) last announced its quarterly earnings data on Thursday, May 9th. The biotechnology company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.33). The business had revenue of $77.06 million during the quarter, compared to analysts’ expectations of $102.00 million. During the same period in the previous year, the company earned ($0.89) earnings per share. On average, equities analysts expect that Coherus BioSciences, Inc. will post -0.76 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the company. HC Wainwright raised their price target on Coherus BioSciences from $11.00 to $12.00 and gave the stock a “buy” rating in a research report on Friday, May 10th. Truist Financial dropped their target price on Coherus BioSciences from $8.00 to $7.00 and set a “buy” rating on the stock in a research report on Monday, May 13th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $8.83.

Coherus BioSciences Company Profile

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.